Area of research
Endocrinology, Diabetes and Metabolism · Molecular Biology
Research interest
Research interests include Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Pharmacology and Obesity Treatment, and Diet and metabolism studies.
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Association entre une meilleure perte de poids et une meilleure amélioration de la fonction physique
Le maintien de sémaglutide (2,4 mg/semaine) a permis une amélioration de la qualité de vie liée à la santé
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Obesity in adults: a clinical practice guideline
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial